Date
|
Update
|
05 September 2023
|
Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course.
In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes. |
27 March 2023
|
Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy have been revised. It is anticipated that the appraisal will begin in early-November 2023 when we will write to you about how you can get involved. |
25 October 2022
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |